HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-4889
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy ; volume:13 ; number:11 ; day:18 ; month:11 ; year:2022 ; pages:1-15 ; date:11.2022
Cell death & disease ; 13, Heft 11 (18.11.2022), 1-15, 11.2022
- Urheber
-
Cristofani, Riccardo
Piccolella, Margherita
Montagnani Marelli, Marina
Tedesco, Barbara
Poletti, Angelo
Moretti, Roberta Manuela
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-022-05365-9
- URN
-
urn:nbn:de:101:1-2023013121094426424496
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cristofani, Riccardo
- Piccolella, Margherita
- Montagnani Marelli, Marina
- Tedesco, Barbara
- Poletti, Angelo
- Moretti, Roberta Manuela
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
MEK targeting in N-RAS mutated metastatic melanoma
BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen
Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma
Induction of N-Ras degradation by flunarizine-mediated autophagy
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma
Variation of mutant allele frequency in NRAS Q61 mutated melanomas
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
MEK targeting in N-RAS mutated metastatic melanoma
BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen
Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma
Induction of N-Ras degradation by flunarizine-mediated autophagy
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma
Variation of mutant allele frequency in NRAS Q61 mutated melanomas
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
MEK targeting in N-RAS mutated metastatic melanoma
BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen
Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma
Induction of N-Ras degradation by flunarizine-mediated autophagy
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma